Skip to content

Team

Our management and team have extensive experience in the discovery and clinical development of small molecule therapeutics focused on immunology targets.

MANAGEMENT

PHOTO-2020-06-17-21-26-04-raju

Raju Mohan, PhD

Founder, CEO & Director
John3-IMG_1332-1200w

John Nuss, PhD

Chief Scientific Officer
Dick-Gregg-Photo-web

Richard Gregg, MD

Chief Medical Officer

chris2-img_1339-1200w

Chris Krueger, JD, MBA

Chief Business Officer
Kathleen Ogilvie Portrait

Kathy Ogilvie, PhD

Vice President,
Translational Pharmacology and Research Operations
Fei-Liu-bio-1000w

Fei Liu, PhD

Principle Scientist,
Immunology

Clinical Advisory Board

James G. Krueger, MD, PhD

Rockefeller University
New York, NY


Director, Milstein Medical Research Program
D. Martin Carter Professor in Clinical Investigation

William Sandborn, MD

University of California
San Diego, CA


Chief, Division of Gastroenterology
Director, Inflammatory Bowel
Disease Center
Professor of Medicine

Emma Guttman, MD, PhD

Icahn School of Medicine at Mount Sinai
New York, NY


Professor of Dermatology and Immunology
Vice Chair, Department of Dermatology

Alexa Boer Kimball, MD, MPH

Beth Israel Deaconess Medical Center & Harvard Medical School
Boston, MA

President and CEO of Harvard Medical Faculty Physicians
Professor of Dermatology at Harvard Medical School

INVESTORS

Ventyx Biosciences is backed by New Science Ventures, a New York and London-based venture capital firm which invests in companies that utilize novel scientific approaches in the Life Sciences and Information Technology sectors.

Raju Mohan, PhD

Founder, Chief Executive Officer & Director

Raju founded Ventyx Biosciences and has served as a member of our board of directors since the company’s inception. Prior to Ventyx, Raju founded Akarna Therapeutics, which was acquired by Allergan in 2016 for up to $1.2B. In addition to Ventyx, Raju has founded Oppilan Pharma, Zomagen Biosciences and Vimalan Biosciences, all immunology-focused specialty pharmaceutical companies. From 2006 to 2011, Raju served as Vice President and head of the San Diego site for Exelixis and Vice President of Chemistry at X-Ceptor Therapeutics (acquired by Exelixis). Raju started his pharmaceutical career at Berlex Biosciences, a subsidiary of Bayer/Schering AG where he held positions of increasing responsibility. Raju is responsible for the discovery of multiple small molecule drug candidates that have entered clinical trials. He is the inventor of MINNEBRO®, an approved therapeutic for hypertension. He has published extensively in peer-reviewed journals and is an inventor on 64 issued US patents. Raju received a PhD in Chemistry from the University of Illinois and a Master’s degree from the Indian Institute of Technology.

John Nuss, PhD

Chief Scientific Officer

John brings more than 25 years of small molecule drug discovery and development experience to the company, primarily in the areas of immunology, inflammation, oncology, and metabolic disease. Prior to joining Ventyx, John was Vice President of Drug Discovery at the Ferring Research Institute where he was responsible for global drug discovery activities. John also previously served as Senior Vice President of Chemistry at Exelixis. Under his leadership, his teams have advanced more than 30 molecules into the clinic. He is the co-inventor of the approved therapeutics COMETRIQ®/CABOMETYX® and MINNEBRO®, and led the team that discovered COTELLIC®. Earlier in his career he held positions of increasing responsibility in discovery at Chiron and served as an Assistant Professor of Chemistry at the University of California, Riverside. John has more than 80 publications and 30 issued patents. He received a bachelor’s degree in chemistry from the University of Kansas, a PhD in organic chemistry from the University of Wisconsin, Madison, and was an NIH postdoctoral fellow in organic synthesis at Stanford University.

Richard Gregg, MD

Chief Medical Officer

Dick Gregg has served as our Chief Medical Officer since 2019. Prior to joining Ventyx Biosciences, Dick was Chief Scientific Officer at Vitae Pharmaceuticals, where he was responsible for all drug discovery and early development activities. Prior to Vitae, Dr. Gregg spent 19 years leading various groups at Bristol-Myers Squibb, including roles as Vice President of Clinical Discovery, where he was responsible for early clinical development, clinical pharmacology, translational medicine and biomarker technologies, and as Vice President of Metabolic and Cardiovascular Drug Discovery. Dick earned his MD from Stanford University School of Medicine, and is board certified in Internal Medicine and in Endocrinology and Metabolism.

Chris Krueger, JD, MBA

Chief Business Officer

Chris has served as our Chief Business Officer since the company’s inception. Prior to Ventyx Biosciences, Chris was Chief Business Officer of Akarna Therapeutics, which was acquired by Allergan in 2016 for up to $1.2B. Chris has negotiated and closed a broad range of strategic partnerships, R&D collaborations, technology licenses and mergers and acquisitions. He has completed numerous equity and debt financings, including IPOs, PIPEs, preferred stock financings and convertible debt offerings. Previously, Chris served as a senior executive at Ardea Biosciences (acquired by AstraZeneca), Xencor, X-Ceptor Therapeutics (acquired by Exelixis) and Aurora Biosciences (acquired by Vertex Pharmaceuticals) with operational responsibility and leadership for multiple functional areas, including business development, legal affairs and corporate finance. Earlier in his career, he was a corporate lawyer at Cooley LLP. Chris received a JD and an MBA in Finance from the University of Southern California and a BA in Economics from the University of California, San Diego.

Kathy Ogilvie, PhD

Vice President, Translational Pharmacology and Research Operations

Kathy serves as Vice President, Translational Pharmacology and Research Operations for Ventyx Biosciences. Kathy is responsible for managing the pharmacology and translation readouts from the Ventyx program. In addition, Kathy also manages the strategic execution of non-clinical development activities. Prior to Ventyx, Kathy held positions of increasing responsibility with several companies, including Ligand Pharmaceuticals, Pfizer, Exelixis, and aTyr Pharma. She has advanced several molecules to clinical development and has published 35 papers in peer-reviewed journals. Kathy received her post-doctoral training at the Salk Institute for Biological Studies and earned her PhD in Biological Sciences from the University of Delaware.

Fei Liu, PhD

Principle Scientist, Immunology

Fei Liu has served as the lead biologist for Ventyx Biosciences since the company’s inception. With over 20 years of experience in anti-viral immunology and inflammation, Fei has overseen or supported multiple areas of pre-clinical development including assay development, DMPK, in vivo pharmacology and in vitro toxicology. Prior to joining Ventyx Biosciences, Fei was a senior scientist at Affymetrix. Fei received a PhD in immunology from the Scripps Research Institute and was a postdoctoral fellow at the Salk Institute.